AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00609089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
Study NCT02769689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
Study NCT02769689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
Study NCT02769689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab (NTZ)
Description: Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
Study NCT02769689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimob (FTY)
Description: Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
Study NCT04628754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and protein
Description: Home based exercise regime and dietary protein guidance
Study NCT04401345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.2 MG/ML
Description: In this group, the patients will receive glycopyrrolate 0.2 mg in 1 ml
Study NCT04653688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The FeetMe® Evaluation
Description: The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
Study NCT05156697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsinoids + Exercise
Description: 60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + supplementation with 12 mg of dihydrocapsiate (7 min before starting the aerobic exercise)
Study NCT05156697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Exercise
Description: 60 minutes of aerobic exercise (cycle-ergometer) at FATmax intensity + placebo pills (7 min before starting the aerobic exercise)
Study NCT01866839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graft Manipulation (CD34+ Selection)
Study NCT01721304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Conjoint Analysis
Description: Computerized survey to elicit patient preferences
Study NCT01171755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine TS-1
Description: Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA\<1.25 M2, 80 mg/day; 1.25 M2≤BSA\<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
Study NCT00535405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Description: Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Study NCT00535405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/simvastatin 20 mg
Description: Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
Study NCT00535405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Description: Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Study NCT01465984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
Study NCT04653688 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: The FeetMe® Evaluation
Description: The FeetMe® Evaluation device is a medical device (class Im CE 0459) for ambulatory gait analysis, consisting of a pair of connected insoles and an Android mobile application.
Study NCT04653688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the PKG® Watch,
Description: The PKG® provides continuous, objective, ambulatory assessment of the treatable and disabling symptoms of Parkinson's disease including tremor, bradykinesia and dyskinesia. The PKG® system consists of a wrist-worn movement recording device known as the PKG® Watch,
Study NCT04653688 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: * an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis
Study NCT04653688 — intervention group
Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: MRI
Description: * an anatomical 3D T1-weigthed gradient-echo sequence (1mm isotropic):~* anatomical registration~* automated segmentation~* volumetric~* texture analysis
Study NCT04653688 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DaTSCAN
Description: * quantify nigrostriatal dopaminergic depletion~* correlate its impact on the type and severity of gait disorders in Parkinson's disease.
Study NCT04401345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: In this group, the patients will receive 1 ml of 0.9% normal saline
Study NCT01689545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual level
Description: Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
Study NCT01689545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural level
Description: Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
Study NCT01689545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual level standard of care
Description: The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
Study NCT01689545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual level standard of care
Description: The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
Study NCT01249638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
Study NCT01249638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: 7.5 mg/kg day 1 q day 21
Study NCT01689545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structural level standard of care
Description: Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
Study NCT01249638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
Study NCT01689545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structural level standard of care
Description: Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
Study NCT01249638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan: 200 mg/m2 day 1 , q day 21
Study NCT03397992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Changing dialysate temperature
Description: Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
Study NCT01637389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Safe Water Program
Description: The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
Study NCT01637389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Safe Water Program
Description: The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (\~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
Study NCT02673567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 - 1
Description: Subcutaneous administration Dose Regimen 1
Study NCT02673567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 - 2
Description: Subcutaneous administration Dose Regimen 2
Study NCT01465984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
Study NCT02673567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-48125 - 3
Description: Subcutaneous administration Dose Regimen 3
Study NCT02673567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT03701997 — intervention group
Intervention type: DEVICE
Intervention: EXCOR Pediatric
Description: Mechanical circulatory support using ventricular assist device
Study NCT01249638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab: 7.5 mg/kg day 1, q day 21
Study NCT00535405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/simvastatin 40 mg
Description: Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
Study NCT00535405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Description: Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Study NCT03909100 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting® System
Description: A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
Study NCT04422392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: (IV, Q3W)
Study NCT04422392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: (IV, Q3W)
Study NCT04422392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed or Nab-paclitaxel
Description: Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
Study NCT04422392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed or Nab-paclitaxel
Description: Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel (Squamous NSCLC) (IV, Q3W)
Study NCT04422392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: (IV, Q3W)
Study NCT06506006 — intervention group
Intervention type: BIOLOGICAL
Intervention: Covid infection
Description: outcome with and without covid infection
Study NCT01711359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT01711359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally
Study NCT00841750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Do not leave a chest tube in the pleural cavity.
Description: At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
Study NCT00841750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Do leave a chest tube in the pleural cavity.
Description: At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
Study NCT01530841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nocturnal ventilation
Description: Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
Study NCT01711359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Administered orally
Study NCT01711359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib Placebo
Description: Baricitinib placebo administered orally once daily.
Study NCT01530841 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal ventilation
Description: Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
Study NCT03448887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova
Description: Extended HD with theranova
Study NCT03448887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Online hemodiafiltration
Description: Online hemodiafiltration
Study NCT01711359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX Placebo
Description: MTX placebo administered orally once weekly.
Study NCT02289976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: core decompression
Description: Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
Study NCT04482387 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DigiVis visual acuity app
Description: Self-testing of visual acuity app on two occasions
Study NCT01366625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal denervation with a catheter-based procedure (Symplicity® Catheter System)
Description: Disruption of the renal nerves with a catheter-based procedure.
Study NCT00005957 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Breast Irradiation
Description: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
Study NCT00005957 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast Radiation plus Regional Radiation
Description: Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
Study NCT02227823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Study NCT02838615 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural steroid (dexamethasone) injection
Description: spinal injections performed in epidural space to relieve chronic low back pain or leg pain
Study NCT00197730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multivitamins - vitamins B complex, C and E
Description: Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
Study NCT00197730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
Study NCT04760912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium used for neuromuscular blokade during anesthesia and anesthesia without rocuronium
Study NCT04760912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia for surgery
Description: General anesthesia with standard anesthetic monitoring,
Study NCT04760912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia for surgery
Description: General anesthesia with standard anesthetic monitoring,
Study NCT01988545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1,5 nmol/kg,GLP-1 sc injection
Study NCT01988545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1,5 nmol/kg,GLP-1 sc injection
Study NCT01988545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1,5 nmol/kg GLP-1 9-36amide, sc injection
Study NCT01988545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1,5 nmol/kg GLP-1 9-36amide, sc injection
Study NCT01988545 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exendin-4 ;10 ug,sc injection
Study NCT01988545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT04485689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin Topical - alone
Description: 5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours
Study NCT04485689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - alone
Description: 5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
Study NCT04485689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin Topical - ice
Description: 5x7 cm2 capsaicin patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
Study NCT04485689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - ice
Description: 5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
Study NCT03476876 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dermacell
Description: Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Dermacell acellular matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
Study NCT01711359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Administered orally every day
Study NCT03476876 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Integra
Description: Subject will receive treatment for one non-healing deep diabetic foot ulcer using one Integra bilayer cross-linked matrix. Subject will be followed up to 16 weeks post treatment, or until wound has closed, whichever comes first.
Study NCT01845727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Amphotericin B at 3%
Study NCT02492360 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample collection
Description: Six tubes of blood will be collected during one blood draw.
Study NCT02492360 — intervention group
Intervention type: BEHAVIORAL
Intervention: Report of peripheral neuropathy after cisplatin therapy
Description: Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
Study NCT03610620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vivascope 2500 ex-vivo fluorescent confocal microscope
Description: scanned with the Vivascope 2500
Study NCT01293643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg clindamycin /800 mg ketoconazole vaginal ovule
Description: 1 vaginal ovule for 3 consecutive days
Study NCT01293643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
Description: 1 applicator (4 g) full of cream intravaginally for 7 to 10 days